Compare Amgen, Inc. (AMGN) vs Symbotic Inc (SYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Symbotic Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Symbotic Inc trades at $43.4 (market cap $5.55B). The key difference: Amgen, Inc. is far larger — about 35.3× Symbotic Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| AMGN | SYM | |
|---|---|---|
Market Cap | $196.12B | $5.55B |
Sector | Health | Technology |
52-Week High | $388.16 | $87.30 |
52-Week Low | $271.18 | $38.57 |
Enterprise Value | $241.41B | $3.54B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SYM trades at $43.64, up 1.14% with neutral technical signals. The company reported $2.25B revenue in 2025 but a net loss of $16.94M, though margins are improving. Recent acquisition of ARMS Innovations expands warehouse automation capabilities. Analyst consensus is bullish with a $57.50 price target, representing 32% upside potential from current levels.
Outlook remains positive due to strong revenue growth and expanding automation market, but profitability challenges and competitive pressures present risks. The stock offers growth potential but requires monitoring of earnings trajectory and market position in the evolving robotics sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
